Sorrento Therapeutics Past Earnings Performance
Past criteria checks 0/6
Sorrento Therapeuticshan disminuido a un ritmo medio anual de -27.1%, mientras que en la industria Biotechs los ingresos han sido de growing a 17.4% anuales. Los ingresos han sido growing a una tasa media anual de 5.2%.
Key information
-27.1%
Earnings growth rate
6.3%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 5.2% |
Return on equity | n/a |
Net Margin | -852.6% |
Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
Recent updates
Sorrento unit Scilex pre-emptively pays off remaining notes for $39.7M
Sep 29Sorrento Sofusa drug delivery system shows promise vs subcutaneous injection in trial
Sep 15Sorrento stock rises 13% on FDA fast track status for low back pain therapy SP-103
Aug 31Sorrento achieves positive results in pivotal trial for abivertinib in NSCLC
Aug 23Sorrento's unit Scilex inks distribution deal for pain drug ZTlido with CH Trading
Aug 17Is Sorrento Therapeutics (NASDAQ:SRNE) A Risky Investment?
Jul 22Sorrento Therapeutics: The Enigma
Jul 15Sorrento Therapeutics subsidiary Scilex to acquire Ancora Medical
Jul 07Sorrento Therapeutics: Sales Are Up But EY Identifies Internal Control Issues
Mar 15Sorrento Therapeutics: Wide Oncology Pipeline, And Watch Out For COVID Updates
Oct 09Revenue & Expenses BreakdownBeta
How Sorrento Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 23 | 64 | -548 | 194 | 0 |
31 Mar 23 | 61 | -672 | 193 | 0 |
31 Dec 22 | 63 | -573 | 182 | 0 |
30 Sep 22 | 60 | -494 | 198 | 0 |
30 Jun 22 | 55 | -524 | 196 | 0 |
31 Mar 22 | 57 | -472 | 198 | 0 |
31 Dec 21 | 53 | -428 | 197 | 0 |
30 Sep 21 | 51 | -355 | 183 | 0 |
30 Jun 21 | 51 | -320 | 159 | 0 |
31 Mar 21 | 47 | -231 | 133 | 0 |
31 Dec 20 | 40 | -298 | 116 | 0 |
30 Sep 20 | 42 | -290 | 100 | 0 |
30 Jun 20 | 36 | -270 | 101 | 0 |
31 Mar 20 | 33 | -249 | 105 | 0 |
31 Dec 19 | 31 | -292 | 104 | 0 |
30 Sep 19 | 25 | -279 | 101 | 0 |
30 Jun 19 | 24 | -262 | 96 | 0 |
31 Mar 19 | 21 | -279 | 79 | 0 |
31 Dec 18 | 21 | -204 | 64 | 0 |
30 Sep 18 | 35 | -105 | 51 | 0 |
30 Jun 18 | 152 | -60 | 42 | 0 |
31 Mar 18 | 153 | 0 | 39 | 0 |
31 Dec 17 | 152 | 9 | 38 | 0 |
30 Sep 17 | 135 | -57 | 41 | 0 |
30 Jun 17 | 16 | -39 | 36 | 0 |
31 Mar 17 | 12 | -68 | 32 | 0 |
31 Dec 16 | 8 | -61 | 24 | 0 |
30 Sep 16 | 5 | -67 | 24 | 0 |
30 Jun 16 | 4 | -83 | 24 | 0 |
31 Mar 16 | 5 | -51 | 22 | 0 |
31 Dec 15 | 5 | -46 | 22 | 0 |
30 Sep 15 | 4 | -31 | 13 | 0 |
30 Jun 15 | 4 | -38 | 10 | 0 |
31 Mar 15 | 4 | -35 | 9 | 0 |
31 Dec 14 | 4 | -35 | 10 | 0 |
30 Sep 14 | 3 | -37 | 10 | 0 |
30 Jun 14 | 2 | -33 | 9 | 0 |
31 Mar 14 | 1 | -29 | 8 | 0 |
31 Dec 13 | 0 | -22 | 6 | 0 |
30 Sep 13 | 0 | -12 | 4 | 0 |
30 Jun 13 | 1 | -10 | 4 | 0 |
31 Mar 13 | 1 | -6 | 3 | 0 |
Beneficios de calidad: SRNE.Q actualmente no es rentable.
Creciente margen de beneficios: SRNE.Q actualmente no es rentable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Tendencia de beneficios: SRNE.Q no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 27.1% al año.
Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de SRNE.Q en el último año con su media de 5 años, ya que actualmente no es rentable.
Beneficios vs. Industria: SRNE.Q no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el del sector Biotechs (-42.7%).
Return on Equity
Alto ROE: SRNE.QEl pasivo de la empresa supera su activo, por lo que es difícil calcular su Rentabilidad de los fondos propios.